Skip to Content
Merck
  • Sodium butyrate epigenetically modulates high-fat diet-induced skeletal muscle mitochondrial adaptation, obesity and insulin resistance through nucleosome positioning.

Sodium butyrate epigenetically modulates high-fat diet-induced skeletal muscle mitochondrial adaptation, obesity and insulin resistance through nucleosome positioning.

British journal of pharmacology (2015-01-07)
Tara M Henagan, Barbara Stefanska, Zhide Fang, Alexandra M Navard, Jianping Ye, Natalie R Lenard, Prasad P Devarshi
ABSTRACT

Sodium butyrate (NaB), an epigenetic modifier, is effective in promoting insulin sensitivity. The specific genomic loci and mechanisms underlying epigenetically induced obesity and insulin resistance and the targets of NaB are not fully understood. The anti-diabetic and anti-obesity effects of NaB treatment were measured by comparing phenotypes and physiologies of C57BL/6J mice fed a low-fat diet (LF), high-fat diet (HF) or high-fat diet plus NaB (HF + NaB) for 10 weeks. We determined a possible mechanism of NaB action through induction of beneficial skeletal muscle mitochondrial adaptations and applied microccocal nuclease digestion with sequencing (MNase-seq) to assess whole genome differences in nucleosome occupancy or positioning and to identify associated epigenetic targets of NaB. NaB prevented HF diet-induced increases in body weight and adiposity without altering food intake or energy expenditure, improved insulin sensitivity as measured by glucose and insulin tolerance tests, and decreased respiratory exchange ratio. In skeletal muscle, NaB increased the percentage of type 1 fibres, improved acylcarnitine profiles as measured by metabolomics and produced a chromatin structure, determined by MNase-seq, similar to that seen in LF. Targeted analysis of representative nuclear-encoded mitochondrial genes showed specific repositioning of the -1 nucleosome in association with altered gene expression. NaB treatment may be an effective pharmacological approach for type 2 diabetes and obesity by inducing -1 nucleosome repositioning within nuclear-encoded mitochondrial genes, causing skeletal muscle mitochondrial adaptations that result in more complete β-oxidation and a lean, insulin sensitive phenotype.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Nitrogen, ≥99.998%
Sigma-Aldrich
Sodium butyrate, 98%
Sigma-Aldrich
DAPI, for nucleic acid staining
Sigma-Aldrich
13C-Short Chain Fatty Acids Stool Mixture, Suitable for mass spectrometry
Sigma-Aldrich
13C-Short Chain Fatty Acids Plasma Mixture, Suitable for mass spectrometry
Sigma-Aldrich
Short Chain Fatty Acid Kit, 0.2μM filtered
Sigma-Aldrich
Citrate Concentrated Solution, BioUltra, for molecular biology, 1 M in H2O
Sigma-Aldrich
Citric acid trisodium salt, ≥98% (GC), anhydrous
Sigma-Aldrich
Citrate Concentrated Solution, BioReagent, suitable for coagulation assays, 4 % (w/v)
Sigma-Aldrich
Monoclonal Anti-Myosin (Skeletal, Slow) antibody produced in mouse, clone NOQ7.5.4D, ascites fluid
Sigma-Aldrich
Insulin solution human, sterile-filtered, BioXtra, suitable for cell culture